(Axios) – Food and Drug Administration commissioner Marty Makary’s flagship effort to overhaul how the agency reviews drugs is facing intensifying scrutiny from Congress and the medical establishment over whether it’s putting politics over science.

The big picture: The Commissioner’s National Priority Voucher program isintended to expedite reviews of drugs and biologics that are “aligned with U.S. national health priorities.” (Read More)